Year to Date: $589.33M
Astellas Pharma US Inc.
Triggered by Astellas' resubmission of the NDA with the FDA seeking approval of the intravenous formulation of vernakalant hydrochloride for the acute conversion of atrial fibrillation (12/18)
BioOne Corp. (Singapore)
Triggered by CE mark regulatory approval for the Intercept Blood System for plasma in Europe; Baxter Healthcare Corp. got $0.5M of the payment; another $5M milestone was expected in January (12/26)
iCo Therapeutics Inc. (Canada)
Triggered by iCo's filing of an IND to begin trials of iCo-007 for treating eye diseases (12/21)
Merck & Co. Inc.
Triggered by Merck's initiation of clinical development of a compound discovered in their funded research collaboration (12/5)
Serono SA (Switzerland; NYSE:SRA)
Triggered by completion of two single-agent Phase II trials of adecatumumab (MT201) in metastatic breast and prostate cancers (12/4)
Neurocrine Biosciences Inc. (NBIX)
GlaxoSmithKline plc (UK)
Triggered by GSK's initiation of Phase II trials of a corticotropin releasing factor R1 receptor antagonist in social anxiety disorder and irritable bowel syndrome (12/20)
AstraZeneca plc (UK)
Triggered by AstraZeneca's decision to continue development of AZD3480 (TC-1734) in Alzheimer's disease and cognitive deficits in schizophrenia (12/27)
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
Currency conversions are based on exchange rates at the time of the deal.
ND = Not disclosed.
NYSE = New York Stock Exchange.